Manufacturing Execution Systems (MES) hold renewed promise as a potential competitive advantage for life science organisations as our industry’s manufacturing network is under unprecedented pressure to reduce costs of goods sold (COGs), maximise global capabilities, and address new regulatory concerns. Simultaneously, our customers’ automation control strategy must be able to react to a changing market faced with patent expiry, the shift from small molecule to large molecule and the future of personalised medicine and new drug delivery systems.
Unfortunately, the same challenges that have existed for the last 20 years regarding MES initiatives exist today and often in an enhanced, more complex form. What is the collective history of MES and what can we learn? How do you design a solution? What are the special challenges we will face? How is it cost justified? These are some of the questions which the authors addresses in the article.
Read the full article
The article was published in Pharmaceutical Engineering, volume 31, no. 4.
About the author
Dr. Gilad Langer is senior MES consultant with NNE Pharmaplan. He has 15 years of experience with helping global customers in selecting, implementing and maximising their MES applications and is recognised as a leader in his field. He has multiple publications regarding advanced control systems and has been involved in strategic development projects in both the United States and Europe.